secwatch.observer — SEC 8-K summary
======================================

Issuer:     OPKO HEALTH, INC. (OPK)
CIK:        0000944809
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0001437749-24-005707
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OPKO Health Q4 revenue $181.9M; net loss narrows to $0.09/sh; $230M convertible notes issued
--------------------------------------------------------------------------------

- Consolidated revenue $181.9M vs $185.4M in prior-year quarter; net loss $65.5M ($0.09/sh) vs $85.2M ($0.11/sh).
- Diagnostics segment revenue fell 11% to $124.2M on lower reimbursement and COVID-19 testing decline.
- Pharmaceuticals revenue rose to $43.0M, driven by international operations and RAYALDEE sales of $9.3M.
- After quarter end, OPKO sold $230M of 3.75% convertible senior notes due 2029 and used $50M to repurchase stock.
- BioReference Health REACH program reduced annualized expenses by $10.1M; operating loss $42.3M including $4.7M non-recurring.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/944809/000143774924005707/0001437749-24-005707-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/944809/000143774924005707/opk20240226_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-005707

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer